Literature DB >> 2750868

Autoimmune inner ear disease: therapy.

B F McCabe1.   

Abstract

Sixty-six patients with this disease have been treated to date with cyclophosphamide and prednisolone resulting in significant improvement in hearing. In some patients the vestibular compartment may be involved as well, but the clinical pattern is significantly different enough from Meniere's disease to distinguish it by the careful historian. The cornerstone of treatment is cyclophosphamide, abetted by prednisolone. A test of treatment is to date the best method of determining who to treat for cure.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2750868

Source DB:  PubMed          Journal:  Am J Otol        ISSN: 0192-9763


  14 in total

1.  Biomarkers of Systemic Inflammation and Risk of Incident Hearing Loss.

Authors:  Shruti Gupta; Sharon G Curhan; Gary C Curhan
Journal:  Ear Hear       Date:  2019 Jul/Aug       Impact factor: 3.570

Review 2.  Immunosuppressive therapy for autoimmune inner ear disease.

Authors:  Maria C Buniel; Katie Geelan-Hansen; Peter C Weber; Vincent K Tuohy
Journal:  Immunotherapy       Date:  2009-05       Impact factor: 4.196

3.  Alternatives to systemic steroid therapy for refractory immune-mediated inner ear disease: A physiopathologic approach.

Authors:  José Ramón García-Berrocal; Andrés Ibáñez; Antonio Rodríguez; José Angel González-García; José María Verdaguer; Almudena Trinidad; Rafael Ramírez-Camacho
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-06-27       Impact factor: 2.503

4.  Inner ear drug delivery via a reciprocating perfusion system in the guinea pig.

Authors:  Zhiqiang Chen; Sharon G Kujawa; Michael J McKenna; Jason O Fiering; Mark J Mescher; Jeffrey T Borenstein; Erin E Leary Swan; William F Sewell
Journal:  J Control Release       Date:  2005-11-07       Impact factor: 9.776

Review 5.  Inner ear drug delivery for auditory applications.

Authors:  Erin E Leary Swan; Mark J Mescher; William F Sewell; Sarah L Tao; Jeffrey T Borenstein
Journal:  Adv Drug Deliv Rev       Date:  2008-09-21       Impact factor: 15.470

Review 6.  Biological and clinical aspects of autoimmune inner ear disease.

Authors:  A J Griffith
Journal:  Yale J Biol Med       Date:  1992 Jan-Feb

Review 7.  Inflammatory and immune responses in the cochlea: potential therapeutic targets for sensorineural hearing loss.

Authors:  Masato Fujioka; Hideyuki Okano; Kaoru Ogawa
Journal:  Front Pharmacol       Date:  2014-12-23       Impact factor: 5.810

8.  Experimental study of local inner ear gene therapy for controlling autoimmune sensorineural hearing loss.

Authors:  Chang-qiang Tan; Xia Gao; Wen-jun Cai; Xiao-yun Qian; Ling Lu; He Huang
Journal:  Biomed Res Int       Date:  2014-04-07       Impact factor: 3.411

Review 9.  Immune system of the inner ear as a novel therapeutic target for sensorineural hearing loss.

Authors:  Takayuki Okano
Journal:  Front Pharmacol       Date:  2014-09-02       Impact factor: 5.810

10.  Activation of TRAIL-DR5 pathway promotes sensorineural degeneration in the inner ear.

Authors:  Shyan-Yuan Kao; Vitor Y R Soares; Arthur G Kristiansen; Konstantina M Stankovic
Journal:  Aging Cell       Date:  2016-01-21       Impact factor: 9.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.